Study of Oasis Ultra in Diabetic Foot Ulcers

Diabetic Foot Ulcer Clinical Trial

Official title:

A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01835379
• Other study ID #: 815-999-09-010
• Status: Completed
• Phase: Phase 4
• First received: April 16, 2013
• Last updated: January 20, 2015
• Start date: May 2013
• Est. completion date: September 2014

Study information

• Verified date: January 2015
• Source: Healthpoint
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra. The hypothesis to be tested is that application of Oasis Ultra will cause more diabetic foot ulcers to heal than wounds treated with regular medical care. Subjects will have their diabetic foot wounds treated for up to 12 weeks with Oasis Ultra or regular medical care .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.

• Subjects 18 years of age or older of either sex with a history of diabetes mellitus (Type 1 or 2) requiring medication (insulin and/or oral/injectable) to control blood glucose levels.

• A non-healing, Wagner grade 1 or 2, neuropathic diabetic foot ulcer.

• Willing and able to make all required study visits.

• Able to follow instructions.

• An ulcer present on any part of the plantar surface of the foot, which is 0.5 cm2 to 10 cm2 (inclusive), as measured at the Screening Visit prior to debridement, with a duration = 6 weeks (documented in the patient's history or by patient report of onset) but not more than 12 months.

• Separation of at least 5 cm (wound edge to wound edge) if = 2 wounds are present.

• Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and = 1.1. If the ABI is greater than 1.1, then a toe pressure of > 40 mmHg OR a transcutaneous oxygen pressure (TcPO2) = 40 mmHg must be present. Either toe pressure or TcPO2 is also acceptable in lieu of ABI, but if both are obtained, each must meet its respective cutoff.

Alternatively, a Doppler waveform consistent with adequate flow to the region of the foot with the target ulcer (biphasic or triphasic waveforms) is acceptable (test result must be included in the source document).

• Target ulcer is not infected based on clinical assessment.

• Able to perform any required dressing changes at home or have a caregiver who can perform the dressing changes.

• Willing to use an appropriate off-loading device to keep weight off of foot ulcers.

• Blood counts and blood chemistry values as follows:

• Alanine aminotransferase (ALT) = 3x upper limit of normal

• Aspartate aminotransferase (AST) = 3x upper limit of normal

• Serum albumin = 2.0 g/dL •Pre-albumin levels of = 10 mg/dL

• Alkaline phosphatase = 500 U/L •Serum total bilirubin = 3.0 mg/dL

• Serum BUN < 75 mg/dL •Serum creatinine = 4.5 mg/dL

• HbA1c = 12% •Hemoglobin (Hgb) > 8.0 g/dL

• WBC > 2.0 x 109/L •Absolute neutrophil count > 1.0 x 109/L

• Platelet count > 50 x 109/L

Exclusion Criteria:

• Contraindications or hypersensitivity to the use of the study device or its components (e.g., porcine sensitivity).

• Participation in another investigational study within thirty (30) days of Visit 1 or planned participation overlapping with this study.

• Subjects with evidence of gangrene on either lower limb.

• Ulcers that require negative pressure or hyperbaric oxygen therapy.

• The Medical Monitor may declare any subject ineligible for a valid medical reason.

• Current treatment with disallowed medications or therapies. Subjects may not be enrolled into the study while using systemic antibiotics.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer
• Ulcer

Intervention

Device:
• Oasis
Oasis Ultra will be applied once per week for up to 12 weeks.

Other:
• Standard

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Healthpoint

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Wounds Closed		At the end of 12 Weeks	No
Secondary	Time to Wound Closure	Kaplan-Meier (K-M) analysis was employed to estimate the median time in weeks to complete ulcer closure.	During the 12 Week treatment period	No